Trevi Therapeutics, Inc. (TRVI) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Trevi Therapeutics reported revenue of $0. Net income was -$42.8M, or -$0.32 per diluted share. Operating activities generated -$42.1M of cash, leaving -$42.1M of free cash flow. At fiscal year end, Trevi Therapeutics held $193.4M in total assets against $10.2M in total liabilities, including $18.9M of cash and equivalents.
Open the full interactive Trevi Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Trevi Therapeutics Key Stats
| Share Price | $12.29 |
|---|---|
| Market Cap | $1.92B |
| 52-Week Range | $9.71 – $19.50 |
| Shares Outstanding | 156.6 million (basic, 2026 Q2) |
Trevi Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$32.5M | -$32.5M | -$29.9M | -$33.9M | -$51.5M | -$49.3M |
| Pre-Tax Income | -$32.8M | -$34.0M | -$29.2M | -$29.1M | -$47.9M | -$42.8M |
| Income Tax | -$18,000 | -$21,000 | -$36,000 | -$32,000 | -$30,000 | -$64,000 |
| Net Income | -$32.8M | -$33.9M | -$29.2M | -$29.1M | -$47.9M | -$42.8M |
| Diluted EPS | -$1.81 | -$1.49 | -$0.45 | -$0.29 | -$0.47 | -$0.32 |
Trevi Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$11.8M | -$8.3M | -$13.2M | -$17.8M |
| Diluted EPS | -$0.08 | -$0.06 | -$0.09 | -$0.11 |
Trevi Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $45.0M | $36.8M | $12.6M | $32.4M | $34.1M | $18.9M |
| Current Assets | $46.3M | $38.0M | $122.6M | $87.5M | $109.4M | $191.7M |
| Total Assets | $47.1M | $38.5M | $123.0M | $89.4M | $110.9M | $193.4M |
| Current Liabilities | $5.6M | $12.7M | $13.4M | $5.8M | $10.5M | $9.7M |
| Total Long-Term Debt | $14.0M | $14.5M | $9.2M | — | — | — |
| Total Liabilities | $19.8M | $21.4M | $15.6M | $6.9M | $11.3M | $10.2M |
| Shareholders' Equity | $27.3M | $17.1M | $107.5M | $82.5M | $99.6M | $183.2M |
Trevi Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$29.0M | -$28.9M | -$28.2M | -$31.7M | -$38.3M | -$42.1M |
| Cash From Investing | -$32,000 | — | -$107.4M | $59.4M | -$21.5M | -$94.1M |
| Cash From Financing | $16.7M | $20.8M | $111.3M | -$7.9M | $61.5M | $121.0M |
| Free Cash Flow | -$29.0M | -$29.0M | -$28.3M | -$31.8M | -$38.3M | -$42.1M |
Figures from Trevi Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Trevi Therapeutics financials page for every line item.
Trevi Therapeutics Company Profile
| Ticker | TRVI |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New Haven, Connecticut |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001563880 |
Frequently Asked Questions
What was Trevi Therapeutics' revenue in fiscal 2025?
Trevi Therapeutics (TRVI) reported revenue of $0 for fiscal 2025.
What is Trevi Therapeutics' annual revenue history?
Trevi Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Trevi Therapeutics' net income in fiscal 2025?
Trevi Therapeutics reported net income of -$42.8M for fiscal 2025.
What was Trevi Therapeutics' earnings per share (EPS) in fiscal 2025?
Trevi Therapeutics' diluted EPS was -$0.32 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Trevi Therapeutics generate in fiscal 2025?
Trevi Therapeutics generated -$42.1M of free cash flow in fiscal 2025.
What was Trevi Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Trevi Therapeutics reported revenue of $0.
How many shares of Trevi Therapeutics are outstanding?
Trevi Therapeutics reported a weighted average of 156.6 million basic shares outstanding in 2026 Q2.
What is Trevi Therapeutics' market cap?
Based on its latest closing price, Trevi Therapeutics (TRVI) has a market capitalization of about $1.92B.
When does Trevi Therapeutics' fiscal year end?
Trevi Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Trevi Therapeutics headquartered?
Trevi Therapeutics lists its business address in New Haven, Connecticut in its SEC filings.